Alumis Inc. raised $259M in a upsized funding round to support its clinical-stage biopharmaceutical development.
Amount Raised
$259 Million
Round Type
Series C
Los AngelesBiotechnologyHealthcareHealth CareInvestors
Description
South San Francisco-based clinical-stage biopharmaceutical company Alumis Inc. closed its upsized Series C funding round after securing $259 million from venture capital investors.
Who else raised in Healthcare and Biotechnology around the same time
Companies in the same sectors as Alumis that raised within 45 days of this round, from Fundz verified event records.
- BioLineRx Ltd raised $20M (Pre-Seed) on April 10, 2024.
- Enlaza Therapeutics raised $84M on April 5, 2024.
- Vaccinex raised $1.8M (Seed) on March 29, 2024.
- Vaccinex raised $1.2M (Seed) on March 28, 2024.
- ViaLase raised $38M on March 25, 2024.
- Novabay raised $665K (Seed) on March 24, 2024.
Who to call at Alumis, and when
A new round usually means Alumis is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alumis raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alumis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alumis. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alumis raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Alumis raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.